Treatment Refractory Soft Tissue Myoepithelial Carcinoma With an ARID1A Mutation. Issue 4 (13th May 2023)

• Record Type: Journal Article
• Authors: Ashcroft, Cody R.; Penney, Scott W.; Whiteway, Susan L.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 45:Issue 4(2023)
• Page Start: e539
• Page End: e542
• Publication Date: 2023-05-13
• Subjects: soft tissue myoepithelial carcinoma -- SWI/SNF complex -- ARID1A; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002650
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Soft tissue myoepithelial carcinoma is a rare tumor first reported in the salivary gland. There is considerable tumor heterogeneity between pathology findings, tumor aggressiveness, and response to treatment. Recent molecular testing has identified recurrent genetic changes with PLAG mutations in salivary gland primary tumors and loss of SMARCB1 and EWSR1/FUS gene changes in myoepithelial carcinoma. SMARCB1 is a component of the switch/sucrose nonfermentable (SWI/SNF) complex, an essential cellular regulator. ARID1A is another SWI/SNF complex subunit and is a potent oncogenic driver in other tumor types. In this case, we describe the case of an adolescent/young adult patient with treatment refractory soft tissue myoepithelial carcinoma and a previously unreported ARID1A mutation.